Intervention Review

Erythropoietin or Darbepoetin for patients with cancer

  1. Julia Bohlius1,*,
  2. Jayne Wilson2,
  3. Jerome Seidenfeld3,
  4. Margret Piper3,
  5. Guido Schwarzer4,
  6. Josie Sandercock5,
  7. Sven Trelle6,
  8. Olaf Weingart1,
  9. Susan Bayliss7,
  10. Susan Brunskill8,
  11. Benjamin Djulbegovic9,
  12. Charles Bennett10,
  13. Simon Langensiepen11,
  14. Chris Hyde8,
  15. Andreas Engert1

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 23 MAY 2006

DOI: 10.1002/14651858.CD003407.pub4

Database Title

Additional Information

How to Cite

Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Bennett C, Langensiepen S, Hyde C, Engert A. Erythropoietin or Darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD003407. DOI: 10.1002/14651858.CD003407.pub4.

Author Information

  1. 1

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  2. 2

    University of Birmingham, Dep. Public Health, Birmingham, UK

  3. 3

    Blue Cross and Blue Shield Association, Technology Evaluation Center, Chicago, IL, USA

  4. 4

    German Cochrane Center, Department of Medical Biometry and Statistics, Freiburg, Germany

  5. 5

    University of Birmingham, Dep Public Health, Birmingham, UK

  6. 6

    University of Bern, Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine, Bern, Switzerland

  7. 7

    University of Birmingahm, Dep Public Health and Epidemilogy, Birmingham, UK

  8. 8

    NHS Blood and Transplant, Systematic Review Initiative, Oxford, Oxon, UK

  9. 9

    H. Lee Moffit Cancer Center and Research Institute, Department of Oncology, Tampa, Florida, USA

  10. 10

    VA Chicago Health Care System-Lakeside Division, Health Services Research and Development Program, Chicago, Illinois, USA

  11. 11

    University of Cologne, Department of Internal Medicine I, 50924 Cologne, Germany

*Julia Bohlius, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. julia.bohlius@uk-koeln.de. jbohlius@ispm.unibe.ch.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (61K)Standard (1472K)Full (2400K)

  1. Current Version

    Erythropoietin or Darbepoetin for patients with cancer

    Julia Bohlius, Jayne Wilson, Jerome Seidenfeld, Margret Piper, Guido Schwarzer, Josie Sandercock, Sven Trelle, Olaf Weingart, Susan Bayliss, Susan Brunskill, Benjamin Djulbegovic, Charles Bennett, Simon Langensiepen, Chris Hyde and Andreas Engert

    Article first published online: 21 JAN 2009 | DOI: 10.1002/14651858.CD003407.pub4

Previous versions of this article and their online publication dates

  1. Version 3

    Erythropoietin for patients with malignant disease

    J Bohlius, S Langensiepen, G Schwarzer, J Seidenfeld, M Piper, C Bennet and A Engert

    Article first published online: 19 APR 2006 | DOI: 10.1002/14651858.CD003407.pub3

  2. Version 2

    Erythropoietin for patients with malignant disease

    J Bohlius, S Langensiepen, G Schwarzer, J Seidenfeld, M Piper, C Bennet and A Engert

    Article first published online: 25 JAN 2006 | DOI: 10.1002/14651858.CD003407.pub2

  3. Version 1

    Erythropoietin for patients with malignant disease

    S Langensiepen, J Bohlius, J Seidenfeld, M Piper, C Bennett, G Schwarzer and A Engert

    Article first published online: 22 APR 2002 | DOI: 10.1002/14651858.CD003407

View Full Article (HTML) Summary (61K)Standard (1472K)Full (2400K)